Financial Performance - The company's revenue for Q1 2023 reached ¥160,921,094.30, representing a 67.97% increase compared to ¥95,802,322.64 in the same period last year[4] - Net profit attributable to shareholders was ¥35,068,583.71, up 79.56% from ¥19,529,827.85 year-on-year[4] - The net profit excluding non-recurring gains and losses was ¥34,554,752.28, reflecting a significant increase of 115.38% compared to ¥16,043,324.96 in the previous year[4] - The basic earnings per share rose to ¥0.32, a 77.78% increase from ¥0.18 in the same period last year[4] - The total operating revenue for Q1 2023 was CNY 160,921,094.30, a significant increase of 68% compared to CNY 95,802,322.64 in Q1 2022[16] - The net profit for Q1 2023 reached CNY 35,109,632.51, up 80% from CNY 19,498,070.83 in the same period last year[17] - The earnings per share (EPS) for Q1 2023 was CNY 0.32, compared to CNY 0.18 in Q1 2022, reflecting a 78% increase[17] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥3,246,045,079.45, a 10.80% increase from ¥2,929,704,604.58 at the end of the previous year[4] - The total assets increased to CNY 3,246,045,079.45, compared to CNY 2,929,704,604.58 at the end of Q1 2022, reflecting a growth of approximately 11%[16] - The total liabilities rose to CNY 712,936,666.80, up from CNY 447,445,307.03, marking an increase of about 59%[16] - The total current assets amount to 1,755,101,778.18 yuan, an increase from 1,609,891,239.32 yuan at the beginning of the year[14] - The company has a total of 132,009,767.53 yuan in contract assets[14] Cash Flow - The net cash flow from operating activities improved significantly to -¥3,367,415.62, a 89.81% increase compared to -¥33,055,022.37 in the previous year[4] - The company's cash flow from operating activities showed a positive trend, indicating improved liquidity and operational efficiency[18] - Operating cash inflow for the current period was $156,711,271.26, compared to $104,198,451.75 in the previous period, representing a 50.4% increase[19] - Net cash outflow from operating activities was -$3,367,415.62, an improvement from -$33,055,022.37 in the previous period[19] - Cash inflow from financing activities totaled $250,000,000.00, with a net cash inflow of $247,293,154.72, a significant recovery from -$240,411,585.24 in the previous period[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,106[10] - The largest shareholder, Shao Chunnan, holds 18.72% of shares, totaling 20,250,000 shares[10] - The second largest shareholder, Lou Jinfang, holds 12.48% of shares, totaling 13,500,000 shares[10] Expenses - The company experienced a 116.60% increase in management expenses, totaling ¥30,143,084.38, primarily due to the amortization of equity incentive expenses granted in June 2022[8] - Research and development expenses for Q1 2023 were CNY 44,638,654.42, slightly higher than CNY 44,014,040.32 in Q1 2022, demonstrating continued investment in innovation[16] Contract Liabilities - The company reported a significant increase in contract liabilities to CNY 86,171,587.59, up from CNY 62,612,015.80, indicating strong future revenue commitments[16] - The company's contract liabilities increased by 37.63% to ¥86,171,587.59, driven by new customer orders[7] Cash and Equivalents - Cash and cash equivalents at the end of the period are 1,281,825,787.43 yuan, up from 1,238,789,220.70 yuan at the beginning of the year[14] - The net increase in cash and cash equivalents for the current period was $34,640,839.10, compared to a decrease of -$380,966,463.46 in the previous period[20] - The ending balance of cash and cash equivalents was $1,245,708,720.63, down from $1,628,035,047.39 in the previous period[20] Audit Status - The company’s first quarter report was not audited[21]
百诚医药(301096) - 2023 Q1 - 季度财报